You are here

Alnylam

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Marketwatch

acute hepatic porphyria

Flag link:

FDA clears rare disease therapy from Akcea, Ionis

FDA clears rare disease therapy from Akcea, Ionis

Biopharma Dive

Ionis Pharmaceuticals

hATTR amyloidosis

Flag link:

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Pharmaceutical Business Review

Flag link:

Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis

Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis

CP Wire

hATTR amyloidosis

Flag link:

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Stat

acute hepatic porphyrias

Flag link:

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

CP Wire

hATTR amyloidosis

Flag link:

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

hATTR amyloidosis

Flag link:

FDA Approves Eight Novel Drugs in August

FDA Approves Eight Novel Drugs in August

BioSpace

Kyowa Hakko Kirin

Amicus Therapeutics

Flag link:

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

Motley Fool

ATTR amyloidosis

Flag link:

2 Blockbuster New Drug Launches Making Investors Nervous Right Now

2 Blockbuster New Drug Launches Making Investors Nervous Right Now

Motley Fool

Flag link:

3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro

3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro

Motley Fool

hATTR amyloidosis

Flag link:

2 Reasons Alnylam Stock Fell on a Landmark Drug Approval

2 Reasons Alnylam Stock Fell on a Landmark Drug Approval

Motley Fool

hATTR amyloidosis

Flag link:

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

Motley Fool

Flag link:

After Alnylam’s solo maiden launch, here comes the tricky bit

After Alnylam’s solo maiden launch, here comes the tricky bit

EP Vantage

Flag link:

Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee

Forbes

hATTR amyloidosis

Flag link:

In first, FDA approves RNA interference drug from Alnylam

In first, FDA approves RNA interference drug from Alnylam

Biopharma Dive

hATTR amyloidosis

Flag link:

With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree

Fierce Pharma

Flag link:

Alnylam Pharmaceuticals Is "Launch Ready"

Alnylam Pharmaceuticals Is "Launch Ready"

Motley Fool

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Yahoo/Benzinga

Pain Therapeutics

Vertex Pharmaceuticals

lumacaftor/ivacaftor

Flag link:

The UK's MHRA Grants Early Access to Anlylam's Patisiran

The UK's MHRA Grants Early Access to Anlylam's Patisiran

CP Wire

hATTR amyloidosis

Flag link:

Pages